scholarly journals Second-Generation Antipsychotics in Adolescent Psychiatric Patients: Metabolic Effects and Impact of an Early Weight Change to Predict Longer Term Weight Gain

2018 ◽  
Vol 28 (4) ◽  
pp. 258-265 ◽  
Author(s):  
Frederik Vandenberghe ◽  
Alexandra Najar-Giroud ◽  
Laurent Holzer ◽  
Philippe Conus ◽  
Chin B. Eap ◽  
...  
2011 ◽  
Vol 1 (1) ◽  
pp. 3-5
Author(s):  
Shannon N. Saldaña ◽  
Jaclyn Kawsky

ABSTRACT The use of second generation antipsychotics (SGAs) for the treatment of psychiatric illnesses in children and adolescents is increasing. Adverse effects of SGAs include weight gain, dyslipidemia, insulin resistance, and glucose intolerance that can subsequently progress to diabetes. Data suggest that the metabolic effects of SGAs may be more severe in children and adolescents than in adults. The mechanism of SGA-related weight gain is not fully understood and almost certainly due to a combination of factors. A vital first step to minimize risk and long-term adverse outcomes from SGA treatment is to implement consistent metabolic monitoring.


Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Beatrice A Golomb ◽  
Hayley J Koslik ◽  
Alexis K Bui

Background and Goal: Sleep problems were significantly increased on simvastatin ( simva ) (but not pravastatin) vs placebo in the UCSD Statin Study. Sleep problems on simva predicted glucose rise. Weight gain has also been reported as a statin side effect. We sought to capitalize on existing data to assess whether sleep problems on simva related to weight gain in men. Method: 442 men without known diabetes or CVD were randomized to simva 20mg or placebo for 6 mon. One hundred eighty and 186 completed single-item self-rating of change in sleep problems vs baseline ( Δslpprob ). Weight (lb) was measured at baseline and 6 mon. Missing 6 mon values were imputed. Analyses: A. Regressions stratified by treatment assessed prediction of weight change by Δslpprob, adjusted for baseline weight. B. Regressions assessed prediction of weight change by the interaction term of simva (vs placebo) x Δslpprob, adjusted for the components of the interaction and baseline weight. Since age-related muscle loss may complicate weight change in elderly; and young adults have low vulnerability to metabolic problems, analyses were repeated excluding these groups. Results: A. Increased sleep problems on simva predicted weight gain (significant), but on placebo predicted weight loss (nonsignificant). B. The Δslpprob x simva interaction term significantly predicted weight gain. When that was parceled out, simva, outside of the sleep relationship, negatively predicted weight change. Exclusion of young adults and elderly strengthened significance of findings (Table). Discussion: Sleep problems, which differentially arise on simva, differentially predict weight gain on simva. This expands the metabolic effects to which sleep problems on simva may contribute and might possibly favor mediation by sleep apnea (a reported complication of simva). Once the sleep problem effect is considered, simva use predicted weight loss . The relative contribution of fat vs muscle loss (vs other) requires exploration.


2006 ◽  
Vol 40 (4) ◽  
pp. 626-632 ◽  
Author(s):  
Diana I Brixner ◽  
Qayyim Said ◽  
Patricia K Corey-Lisle ◽  
A Vickie Tuomari ◽  
Gilbert J L'italien ◽  
...  

2011 ◽  
Vol 126 (1-3) ◽  
pp. 117-123 ◽  
Author(s):  
Karen E. Moeller ◽  
Sally K. Rigler ◽  
Angela Mayorga ◽  
Niaman Nazir ◽  
Theresa I. Shireman

2011 ◽  
Vol 26 (S2) ◽  
pp. 250-250
Author(s):  
J. Zhao ◽  
P. Cazorla ◽  
J. Schoemaker ◽  
M. Mackle ◽  
J. Panagides ◽  
...  

IntroductionWeight change and metabolic effects of atypical antipsychotics vary considerably.ObjectiveAssess weight and metabolic effects of asenapine in adults.AimDemonstrate that asenapine marketed doses are well tolerated compared with placebo or olanzapine.MethodsData were from pooled asenapine trials that used placebo (1748 patients; duration: 1−6 wk) and/or olanzapine (3430 patients; duration, 3−>100 wk) controls. Asenapine doses were 5 or 10 mg BID (2–20 mg BID in 2 studies); olanzapine doses were 5–20 mg QD. Post hoc inferential analyses based on ANOVA assessed change from baseline weight, body mass index, and fasting lipid and glucose levels.ResultsTable 1 summarizes the results.[Change From Baseline Weight and Metabolic Paramete]DiscussionThese post hoc pooled analyses support published reports and suggest asenapine was associated with moderate weight gain and increased fasting triglyceride and glucose levels vs placebo, but lower propensity for weight gain or increased serum lipids (ie, triglycerides, low-density lipoprotein, and cholesterol) vs olanzapine.


2014 ◽  
Vol 24 ◽  
pp. S710-S711
Author(s):  
C.M. Díaz-Caneja ◽  
L. Pina-Camacho ◽  
D. Fraguas ◽  
A. González-Pinto ◽  
R. Rodríguez-Jiménez ◽  
...  

2016 ◽  
Vol 26 ◽  
pp. S738-S739
Author(s):  
C.M. Díaz-Caneja ◽  
L. Pina-Camacho ◽  
D. Fraguas ◽  
P.A. Saiz ◽  
I. Corripio ◽  
...  

2015 ◽  
Vol 115 (7) ◽  
pp. 60
Author(s):  
L. M. Vasilenko ◽  
L. N. Gorobets ◽  
V. S. Bulanov ◽  
A. V. Litvinov ◽  
G. P. Ivanova ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document